An observational study in Leukemia and Lymphoma, sponsored by The First Affiliated Hospital of Xinxiang Medical College. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-20.
Sponsored by The First Affiliated Hospital of Xinxiang Medical College · Observational
4. Study Population 4.1 Inclusion Criteria Case group
1)≥ 18 years old , regardless of gender; 2)Hematological malignancies confirmed by cytology, histology , or molecular biology , who require subsequent anti-tumor treatment ( chemotherapy , hematopoietic stem cell transplantation, radiotherapy, or cellular immunotherapy ) ; control group
4.2 Exclusion criteria
ii. Statistical analysis of the correlation between serum histone succinylation and tumor efficacy (including chemotherapy , hematopoietic stem cell transplantation, cellular immunotherapy ) and clinical outcomes . ( Efficacy evaluation was performed using RECIST 1.1 criteria )
5,441 studies on the registry are indexed under Leukemia; 636 are open to participants now.
This study's planned enrollment of 200 is above the median of 120 across 744 observational studies indexed under Leukemia.
Browse Leukemia studies →The First Affiliated Hospital of Xinxiang Medical College is the lead sponsor of 41 studies on the registry; 37 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Case group
1)≥ 18 years old , regardless of gender; 2)Non-cancer patients undergoing health checkups;
Exclusion criteria
1)≥ 18 years old , regardless of gender; 2)Non-cancer patients undergoing health checkups;
Exclusion criteria
Control Cohort: 200 healthy volunteers
Other: This is observational studies, participants are not assigned an intervention as part of the study.
This is observational studies, participants are not assigned an intervention as part of the study.
To evaluate the differences in serum histone succinylation levels between patients with hematologic malignancies and healthy individuals
To evaluate the differences in serum histone succinylation levels between patients with hematologic malignancies and healthy individuals, and to confirm whether there is a significant difference in serum histone succinylation levels between these two groups.
Time frame: Baseline
the correlation between serum histone succinylation modification levels and different types of tumors as well as tumor stages
To determine the correlation between serum histone succinylation modification levels and different types of tumors as well as tumor stages, and to statistically analyze the relationship between serum histone succinylation and therapeutic outcomes (including chemotherapy, hematopoietic stem cell transplantation, and cellular immunotherapy) as well as clinical pathological features.
Time frame: through study completion, an average of 1 year
No study locations are listed for this record.
Documents are hosted by the registry — open the source record to download them.
Plan to share: Undecided
This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital of Xinxiang Medical College